A Study to Evaluate the Safety and Immunogenicity of GlaxoSmithKline Biologicals' Influenza Vaccine GSK3206641A Administered in Adults 18 to 64 Years of Age and 65 Years of Age and Older

  • STATUS
    Recruiting
  • End date
    Jun 28, 2022
  • participants needed
    840
  • sponsor
    GlaxoSmithKline
Updated on 22 September 2021
tubal ligation
hysterectomy
vaccination
trivalent influenza vaccine
immunomodulators

Summary

Study to evaluate the safety and immunogenicity of H7N9 antigen in combination with full or half doses of AS03 adjuvant system in healthy adults.

Details
Condition Influenza
Treatment Placebo, FLU-Q-PAN H7N9 Formulation 1, FLU-Q-PAN H7N9 Formulation 2, FLU-Q-PAN H7N9 Formulation 3, AS03B, AS03A
Clinical Study IdentifierNCT04789577
SponsorGlaxoSmithKline
Last Modified on22 September 2021

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note